Immunovant, Inc. IMVT Switzerland — Net operating loss carry forwards
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLossCarryforwards.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
The Company recorded an income tax benefit predominantly related to the internal reorganization, reducing the provision for income taxes to $0.2 million for the year ended March 31, 2026. Further, a new deferred tax asset was created as reflected above related to capitalized research and development expenses that will be deductible in the U.S. in future periods. As of March 31, 2026, the Company has gross net operating loss carryforwards in Switzerland of $279.0 million, which decreased from $1,094.6 million as of March 31, 2025 primarily due to utilization caused by the transfer of intellectual property, and will begin to expire as of March 31, 2032. Additionally, as of March 31, 2026, the Company has gross net operating loss carryforwards in the U.S. of $195.2 million, which increased from $48.7 million as of March 31, 2025, driven by the internal reorganization and can be carried forward indefinitely with utilization limited to 80% of future taxable income. The Company has research and development and orphan drug credit carryforwards in the U.S. of $53.7 million as of March 31, 2026, which begin to expire as of March 31, 2039.
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s switzerland — net operating loss carry forwards?
- Immunovant, Inc. (IMVT) reported switzerland — net operating loss carry forwards of $279M in Q1 2026.
- How has Immunovant, Inc.'s switzerland — net operating loss carry forwards changed year-over-year?
- Immunovant, Inc.'s switzerland — net operating loss carry forwards decreased by 74.5% year-over-year, from $1.09B to $279M.
- What does switzerland — net operating loss carry forwards mean?
- This metric quantifies the accumulated tax losses from the Switzerland segment that can be applied to offset future taxable income in that jurisdiction. It serves as a potential future tax asset that may reduce the company's effective tax rate once the segment reaches profitability. Investors track this to evaluate the long-term tax efficiency and deferred tax benefits associated with the company's international operations.
Ask your AI about Immunovant, Inc.'s switzerland — net operating loss carry forwards.
Connect your AI assistant and compare segments, right in your chat.
